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Single cell transcriptome defined as the entire RNA or polyadenylated products of RNA polymerase II on a cell can
describe the gene regulation networks responsible for physiological functions, behaviours, and phenotypes in
response to signals and microenvironmental changes. Single cell transcriptome/sequencing has the special power
to investigate small groups of differentiating cells, circulating tumour cells, or tissue stem cells. A large number of
factors may influence the extent of single-cell heterogeneity within a system. It is the opportunity that the single-cell
sequencing can be used for the identification of genetic changes in rare cells, e.g. cancer and tissue stem cells, in clinical
samples. The methodologies of single-cell sequencing have been improved and developed with the increase of the
understanding and attention. The clinical research and application of the single cell sequencing analysis are expected to
identify and validate disease-specific biomarkers, network biomarkers, dynamic network biomarkers. The single cell
research and value will be also dependent upon the understanding of genomic heterogeneity, planning and design of
study protocol, representative of selected and targeted cells, and sensitivity and repeatability of the methodology. The
single cell sequencing can be used to develop new diagnostics, monitor disease progresses, measure responses to
therapies, and predict the prognosis of patients, although there are still a large number of challenges and difficulties to
be faced. It would be more values and specificities of the single cell sequencing to integrate with the function of cells,
organs, and systems of the body, the clinical phenotypes of patients, and the description of clinical bioinformatics.
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for physiological functions, behaviours, and phenotypes
in response to signals and microenvironmental changes.
Methods of single cell transcriptome analyses have been
developed and significantly improved with advantages
and disadvantages [1,2]. Single cell transcriptome can
demonstrate the heterogeneity of gene expressions,
interactions and regulations of gene regulatory networks,
subpopulations within a tumour, characteristics of
putative cancer stem cells, gene expression profiles of
intracellular compartments, mRNA locations, allele
specific gene expression, or the information combined* Correspondence: zhuzhitu@163.com; xiangdong.wang@clintransmed.org
1Department of Oncology, Liaoning Medical University Hospital, Jinzhou,
China
4Fudan University Center of Clinical Bioinformatics, Shanghai Respiratory
Research Institute, Fudan University School of Medicine, Zhongshan Hospital,
Shanghai, China
Full list of author information is available at the end of the article
© 2014 Zhu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.with the existing strand-specific cDNA library preparation
strategies. With next generation sequencing, the informa-
tion on both full genome and transcriptome can be
obtained from an individual cell. Single-cell genome
analysis becomes more important in the understanding of
the diversity in microbial ecology, cancer development,
prenatal genetic diagnosis, or human genome structures.
Single cell transcriptome/sequencing has the special
power to investigate small groups of differentiating cells,
circulating tumour cells, or tissue stem cells. Tang et al.
defined the dynamic molecular changes with cell-fate
changes during the conversion from the inner cell mass
cells of blastocysts to pluripotent embryonic stem cells
using RNA-Seq transcriptome analysis at the resolution of
single cells [3]. Molecular mechanisms by which genetic
elements could be switched depend upon the pluripotency,
changes in epigenetic regulators, the stability of the newly
acquired epigenotype, or self-renewal. It should be an
excellent example to further study the regulation and
differentiation of small numbers of stem cells in adults,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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epigenetic regulators, or changes in microRNAs, to identify
targeted genes of pluripotency. Furthermore, single cell
transcriptome was used to measure the frequency of
large-scale genome instability and de novo mutation
rates with distinct characteristics [4].
A large number of factors may influence the extent
of single-cell heterogeneity within a system, e.g. the source
of analyzed tissues, biological conditions or microenviron-
ments of the individual cell. The single cell transcriptome
was suggested to avoid, or at least reduce, the variability of
clinical samples, in order to define new cell classifications,
transitional states, biological distinctions, or biomarkers.
Shalek et al. recently demonstrated that the inflammatory
stimulus lipopolysaccharide could induce an extensive, pre-
viously unobserved, bimodal variation in mRNA abundance
and splicing patterns in bone marrow-derived dendritic
cells using single-cell RNA-Seq analysis [5]. It indicates
that stimuli from autocrine-based or external sources
may initiate the heterogeneity of the cell, different from
the traditional understanding. It is possible that we can
identify and discover more sensitive and specific elements
responsible for the development of cell heterogeneity as
biomarkers to monitor dynamic changes and interactions
of gene regulation networks or develop new molecular or
cellular therapies. The multiplexed primer design can be
introduced for selected targeted genes to lower the pre-
amplification primer concentration and primer dimer
signals, increase the feasibility of measurements, or make
the operation easier for classification of cell type, dissec-
tion of heterogeneity, mapping of cellular hierarchy, and
computational construction of genetic networks [6].
It is the opportunity that the single-cell sequencing
can be used for the identification of genetic changes in
rare cells, e.g. cancer and tissue stem cells, in clinical
samples which may contain hundred cells in body fluids
and biopsy with fine-needle. It seems that one of clinical
applications of single-cell sequencing should be to
understand the genomic profiling of copy number or
sequence mutations in rare cells. The challenge in the
identification and validation of therapeutic targets is to
define the cell heterogeneity, especially to differ between
cancer and pre-cancer cells, activated and non-activated
inflammatory cells, or functional and non-functional
cells, between sampling micro-regions, between cells at
various stages, or between responses to therapy. For
example, our previous studies on genetic comparison of
mouse lung telocytes with mesenchymal stem cells and
fibroblasts demonstrated that about 10-20% of genes
expressed differently between 5 and 10 day cell culture
of lung telocytes per se [7]. It indicates that gene expres-
sions, phenotypes, or functional networks can be varied
in the differentiation process or developmental duration.
Single cell sequencing has been widely considered as thepowerful and helpful tool to identify disease-specific
biomarkers to diagnose and monitor the occurrence and
progress of the disease, as well as the responses of
patients to the treatment. It has been emphasized that
disease-specific biomarkers, network biomarkers, and
dynamic network biomarkers can monitor and predict
the responses to therapies, prognoses of patients, and
reoccurrences of the disease, by integrating genomic/
proteomic profiles with clinical phenotypes [8-12]. It is a
common challenge for those methodologies including
single cell sequencing to define the existence of discovered
genes before the occurrence of the disease, before clinical
diagnosis, or before the application of therapies. It should
be also considered whether the same type of the single cell
can be collected for measuring the genomic heterogeneity
and frequency of resistant clones in the primary disease
before and after a single therapy or multiple manipula-
tions, or during the dynamic follow-up in patients. It is
highly expected to have the single cell sequencing study
with a clear clinical design and definite disease-specific or
associated groups, including similar diagnoses, severities,
stages, genetic backgrounds, pathogeneses, or therapies.
One of critical parts to apply single-cell sequencing
for disease biomarkers should be to integrate clinical
experience and knowledge with bioinformatics from
the single cell sequencing and ensure the understanding
of diseases.
The methodologies of single-cell sequencing have been
improved and developed with the increase of the under-
standing and attention. The single cell sequencing is
expected to detect the genomic heterogeneity in the
primary disease and provide useful information for
selecting therapies, monitoring the efficacy and efficiency
of the therapy, predicting the potential outcomes of
patients, if the disease would be monogenomic one which
hardly exists in clinical practice. It is more important
to consider the interactions between genes, proteins,
cells, organs, as well as the critical role of the tissue micro-
environment, when clinical studies are designed for the
single cell sequencing analysis. Single-cell sequencing was
evidenced to have the high sensitivity in the identification
of rare chemoresistant clones in the primary cancer and
to investigate questions of whether resistant clones were
pre-existing in the primary cancer or appeared in response
to therapies [13]. The challenge to translate single cell
sequencing analysis from clinical research to clinical appli-
cation is to standardize the study design and protocol, the
study and operation process, data analysis and mining,
and the application of clinical bioinformatics. The clinical
application of single cell sequencing per se faces the diffi-
culty of problem-solving or question-based study design,
and defines the criteria of disease-specific diagnosis, moni-
toring, or prediction. On the other hand, the single cell se-
quencing can be used as the tool to screen and identify
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into a diagnostic panel. It is still difficult to develop the
gene panel-based diagnostic kits after the identification,
selection, validation, and optimization from the single cell
sequencing, due to the unexpected barriers, e.g. for stabil-
ity and repeatability of the expression, the representative
of the targeted panel, or description of the measured
results. It is also important to understand the dynamic
existence of genomic variation, interaction between genes,
and definition of gene scale, origin, rate, and nature.
Another potential or new hope is to develop new type
cells for therapies by bioengineering or modifying targeted
genes selected from the single cell sequencing. It believes
that the construction of a phylogenetic tree of a human life-
time and the contribution of genetic heterogeneity to the
organism can be defined and figured out by the single cell
sequencing analysis of the different cells from endodermal,
mesodermal, and ectodermal tissues from an individual.
The sub-classification or new discovered populations of cell
types can be found by gene expression profiles and epigen-
etic status, although the relationship between genome
sequence, epigenetic status, and gene expression, and the
functional capacity of the cell remain unclear [14]. The new
methods have been suggested to expedite applications in
basic genome research and provide novel approaches for
clinical genetic diagnosis [15]. The paired-end sequence
analysis of single-cell whole-genome amplification products
was developed to explore the nature and pace of genome
mutation, the genetic composition, or de novo mutations.
Such exciting approach could detect DNA mutations, DNA
copy number changes from allelic whole-genome amplifica-
tion -amplification, and the break points and architecture of
structural variants. We call the special attention and believe
it is a time to further translate the concept of single-cell
analysis, sequencing, or transcriptomics into clinical
research and application for the identification and valid-
ation of disease-special biomarkers, on basis of recent
emphases from a growing number of outstanding
publications [16-19].
In conclusion, the clinical research and application
of the single cell sequencing analysis are expected to
identify and validate disease-specific biomarkers, network
biomarkers, dynamic network biomarkers. The single cell
research and value will be also dependent upon the under-
standing of genomic heterogeneity, planning and design of
study protocol, representative of selected and targeted cells,
and sensitivity and repeatability of the methodology.
The single cell sequencing can be used develop new
diagnostics, monitor disease progresses, measure responses
to therapies, and predict the prognosis of patients,
although there are still a large number of challenges and
difficulties to be faced. It would be more values and speci-
ficities of the single cell sequencing to integrate with
the function of cells, organs, and systems of the body,the clinical phenotypes of patients, and the description of
clinical bioinformatics.
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